HIV Drug Pipeline: LAI-ART & bNAbs — PatSnap Eureka
Long-Acting Injectable ART, bNAbs & Functional Cure Approaches
HIV-1 infection affects an estimated 38 million people globally. Three converging frontiers — long-acting injectables, broadly neutralizing antibodies, and latent reservoir strategies — are reshaping the antiretroviral development landscape. Explore the innovation signals with PatSnap Eureka.
The Latent Reservoir: Central Barrier to HIV Cure
HIV-1 establishes a state of latent infection in a small pool of resting, memory CD4+ T cells — a reservoir that is not eliminated by even highly effective antiretroviral therapy. Standard combination ART suppresses viremia but does not eradicate the virus, with viral rebound occurring within weeks of treatment discontinuation. This biological reality frames the entire HIV drug development landscape.
Key molecular targets identified across the pipeline include HIV-1 Reverse Transcriptase (RT), targeted by NRTIs and NNRTIs including rilpivirine, islatravir, and doravirine; HIV-1 Integrase (IN), targeted by INSTIs with cabotegravir as the principal long-acting candidate; and the HIV-1 Envelope Glycoprotein (Env/gp120/gp41), the primary target of broadly neutralizing antibodies.
Emerging targets include the HIV-1 Capsid and Gag Polyprotein — with lenacapavir as the clinical exemplar — the CCR5 Coreceptor for both viral entry inhibition and targeted drug delivery, and latency-associated regulatory machinery including NF-κB signaling, PKC isoforms, inhibitor of apoptosis proteins (BIRC2/IAP), and Toll-like receptor 7 (TLR7). The patent analytics landscape reflects a distributed, multi-institutional research ecosystem spanning pharma, biotech, and academia.
- Resting memory CD4+ T cells harbour replication-competent proviral DNA integrated into the host genome
- Viral rebound occurs within weeks of ART discontinuation — no retrieved result demonstrates a reliable human cure
- More than half of investigational long-acting antivirals target HIV-1 RT and/or integrase (Karolinska Institute)
- bNAbs offer Fc-mediated immune effector functions (ADCC, phagocytosis) beyond direct viral neutralisation
Five Frontiers Reshaping HIV Drug Development
From approved long-acting injectables to early-stage gene therapies, the HIV pipeline spans a spectrum of mechanistic approaches and clinical readiness levels.
Long-Acting Injectable Small Molecules (LAI-ART)
Crystalline nanoparticle formulations of cabotegravir (CAB) and rilpivirine (RPV) anchor the most advanced LAI strategy. Phase 3 trials (ATLAS, FLAIR, ATLAS-2M) demonstrated non-inferiority to daily oral ART through 96 weeks, with Q8W dosing equivalent to Q4W. Two Phase 3 PrEP trials were stopped early due to significantly fewer incident HIV infections in the long-acting CAB arm versus daily oral tenofovir/emtricitabine. Lenacapavir, a long-acting capsid inhibitor, is also approved for injectable use in treatment-experienced patients.
CAB+RPV: Approved · Q4W & Q8WBroadly Neutralizing Antibodies (bNAbs)
bNAbs target conserved epitopes on the HIV-1 Env trimer — the CD4 binding site, V2/V3 glycan-dependent sites, and gp41-proximal regions. Compared to small-molecule ART, bNAbs offer reduced toxicity, extended half-lives permitting infrequent dosing, and Fc-mediated immune effector functions (ADCC, phagocytosis) that may contribute to reservoir clearance. The Gilead Sciences SHIV study showed that PGT121 combined with vesatolimod (TLR7 agonist) partially prevented viral rebound following ART discontinuation in chronically infected macaques.
PGT121 · CD4bs · MPER bNAbsGene Therapy & Cell-Based Approaches
Chimeric antigen receptor (CAR) T cell therapy is a re-emerging HIV cure strategy, with improved constructs now advancing to HIV-1 clinical trials. Recombinant adeno-associated virus (rAAV) vectors deliver anti-HIV biologics including bNAbs — a "vectored immunoprophylaxis" approach aiming for durable in vivo expression from a single administration. CRISPR-Cas9 gene editing has enabled complete excision of latent HIV-1 from the host genome in preclinical models, though success has thus far been limited.
CAR-T · rAAV · CRISPR-Cas9Long-Acting Nanoformulations & Implant Systems
Yale University researchers describe a dual modality system — a PLGA-based injectable nanoformulation and a removable subcutaneous implant — delivering a synergistic NNRTI and EFdA combination, controlling HIV-1 infection in a humanized mouse model. A lipid-stabilized nanosuspension (TLC-ART101) containing tenofovir, lopinavir, and ritonavir demonstrated intracellular drug levels in lymph node mononuclear cells persisting for over 2 weeks with apparent terminal half-lives of 65–477 hours in plasma.
PLGA · TLC-ART101 · nanoATVLatency Reversal & Shock-and-Kill Strategies
The shock-and-kill paradigm uses latency-reversing agents (LRAs) to reactivate HIV from transcriptional silence in latently infected CD4+ T cells. PKC agonists such as ingenol-3-angelate (PEP005) activate NF-κB via the PKCδ/θ-IκBα/ε pathway. IAP antagonists such as Debio 1143 activate HIV transcription via non-canonical NF-κB signaling. Mathematical modeling from Fred Hutchinson Cancer Research Center proposes that sustained, modest reservoir clearance outperforms single large-impact interventions.
PEP005 · Debio 1143 · TLR7 agonistsProtein-Based & PEGylated Fusion Inhibitors
A protein-based fusion inhibitor, FLT (FN3-L35-T1144), binds human serum albumin via an albumin-binding domain, achieving a half-life of approximately 27 hours in rats — a strategy to circumvent the short half-life limiting peptide-based inhibitors like enfuvirtide (T20). PEGylated fusion inhibitory peptides (PEG2kC34 and PEG5kC34) derived from the C34 scaffold demonstrated mean EC50 values of approximately 26–32 nM against 47 clinical HIV-1 isolates, with substantially extended plasma half-lives versus unmodified peptides.
FLT · PEG2kC34 · AlbuvirtideHIV Pipeline Data: Targets, Agents & Clinical Signals
Key quantitative signals from patent and literature analysis across the HIV long-acting and cure pipeline, sourced via PatSnap Eureka.
HIV Molecular Targets: Agent Count by Class
Integrase and RT dominate the long-acting pipeline; Capsid and Latency targets are emerging with fewer but high-impact agents.
Key HIV Clinical Milestones by Year
From foundational nanoformulation work (2013) through Phase 3 approvals and SHIV cure studies (2022), the LAI-ART and bNAb pipeline has accelerated significantly.
Albuvirtide Phase 2: Viral Load Suppression by Dose
In a 7-week open-label Phase 2 trial in 20 HIV-1-infected adults, the 320 mg weekly dose of albuvirtide (ABT) achieved HIV RNA below 50 copies/mL in 55.6% of participants.
Emerging HIV Combination Strategies
Six distinct combination approaches are identified in the retrieved literature, ranging from bNAb+TLR7 agonist pairings to CAR-T cells engineered to secrete bNAbs.
HIV Long-Acting & Cure Pipeline: Key Agents & Stage
Key agents identified across retrieved patent and literature records, mapped to target, institution, and current development stage.
| Agent / Approach | Target | Key Institution | Stage | Key Signal |
|---|---|---|---|---|
| CAB + RPV (Q4W / Q8W) | IN + RT | GlaxoSmithKline / ViiV | Approved | Non-inferior to oral ART through 96 weeks (ATLAS, FLAIR, ATLAS-2M) |
| Lenacapavir | Capsid (CA) | Gilead Sciences | Approved | Long-acting injectable for treatment-experienced patients |
| Islatravir (EFdA) | RT (NRTTI) | Merck | Clinical Trials | Promising pipeline agent for PrEP; nucleoside RT translocation inhibitor |
| PGT121 + Vesatolimod | Env gp120 + TLR7 | Gilead Sciences | Clinical Trials | Partial prevention of viral rebound in chronically SHIV-infected macaques (2022) |
| Albuvirtide (ABT) | gp41 Fusion | Nanjing Frontier Biotechnologies | Clinical Trials | 55.6% achieved HIV RNA <50 copies/mL at 320 mg weekly (Phase 2, n=20) |
| CAR-T HIV-specific | Env epitopes | University of Pittsburgh | Early Clinical | Advancing to HIV-1 clinical trials with improved constructs |
| FLT (FN3-L35-T1144) | gp41 Fusion / HSA | Fudan University | Preclinical | ~27h half-life in rats via albumin-binding domain strategy |
Identify White Space in the HIV Nanoformulation IP Landscape
Nanoformulation and targeted delivery platforms are prominently featured in academic literature but underrepresented in patent activity — a potential white space for strategic filing or licensing.
Four Strategic Signals for HIV R&D & IP Teams
Derived directly from retrieved patent and literature records across the HIV long-acting, bNAb, and functional cure pipeline.
LAI-ART Is the Most Clinically Mature Near-Term Opportunity
The CAB+RPV injectable regimen (Q4W and Q8W) has demonstrated Phase 3 efficacy for both treatment and PrEP. Monitor label expansion into new populations and next-generation agents — lenacapavir and islatravir — that may extend injection intervals toward quarterly or semi-annual dosing.
bNAb Combinations Targeting Multiple Env Epitopes Are Essential
Retrieved results consistently emphasise that single bNAbs are insufficient due to HIV's envelope diversity and mutation rate. IP strategies focusing on bispecific antibodies, Fc-enhanced formats, and bNAb combinations targeting non-overlapping epitopes (CD4bs + V3-glycan + MPER) will define the next generation of antibody-based HIV drugs.
Who Is Driving HIV Long-Acting & Cure Innovation?
Activity in this dataset is entirely literature-driven, reflecting a distributed, multi-institutional academic and industry research ecosystem. Gilead Sciences is represented by multiple results spanning LAI formulation, bNAb combinations, and TLR7-based cure strategies, including the 2022 vesatolimod + PGT121 SHIV study. GlaxoSmithKline contributed early foundational work on crystalline nanoparticle formulations of rilpivirine and cabotegravir, directly enabling the approved CAB+RPV injectable product.
Debiopharm International is described as the developer of Debio 1143, an IAP antagonist positioned as a latency-reversing agent. Nanjing Frontier Biotechnologies contributed clinical data on albuvirtide (ABT), a long-acting HIV fusion inhibitor with an 11–12-day half-life, in combination with lopinavir/ritonavir. Explore the full patent analytics landscape for HIV across these organisations using PatSnap.
On the academic side, the University of Nebraska Medical Center contributes multiple results covering nanoformulated ART, macrophage reservoir biology, and LAI adherence data. Fred Hutchinson Cancer Research Center provides mathematical modeling of reservoir clearance. Scripps Research Institute leads on bNAb discovery and rAAV-mediated antibody gene delivery. The clinical trial registry and NIAID track ongoing human studies across these institutions.
The PatSnap customer network includes leading life sciences organisations using Eureka to monitor competitor pipelines, identify licensing opportunities, and track emerging assignees in therapeutic areas including HIV. UNAIDS and WHO also publish annual HIV pipeline reviews relevant to this landscape.
HIV Drug Pipeline — key questions answered
Long-acting injectable ART centres on crystalline nanoparticle formulations of cabotegravir (CAB), an integrase strand transfer inhibitor, and rilpivirine (RPV), an NNRTI. Phase 3 trials (ATLAS, FLAIR, ATLAS-2M) demonstrated non-inferiority to daily oral ART through 96 weeks. CAB+RPV administered every 4 weeks or every 8 weeks are both approved. Lenacapavir, a long-acting capsid inhibitor, is also approved for injectable use in treatment-experienced patients.
Compared to small-molecule ART, bNAbs offer: (1) reduced toxicity, (2) extended half-lives permitting infrequent dosing, and (3) Fc-mediated immune effector functions (ADCC, phagocytosis) that may contribute to reservoir clearance. bNAbs target conserved epitopes on the HIV-1 Env trimer, particularly the CD4 binding site, V2/V3 glycan-dependent sites, and gp41-proximal regions.
HIV-1 establishes a state of latent infection in a small pool of resting, memory CD4+ T cells. This reservoir is not eliminated by even highly effective ART regimens. Standard combination ART suppresses viremia but does not eradicate the virus, with viral rebound occurring within weeks of treatment discontinuation.
The shock-and-kill paradigm uses latency-reversing agents (LRAs) to reactivate HIV from transcriptional silence in latently infected CD4+ T cells, rendering them visible to immune clearance or ART. Strategies include PKC agonists such as ingenol-3-angelate (PEP005), IAP antagonists such as Debio 1143, and TLR7 agonists such as vesatolimod. The Gilead Sciences SHIV study showed that combining the bNAb PGT121 with vesatolimod partially prevented viral rebound in chronically infected macaques.
Recombinant adeno-associated virus (rAAV) vectors are being used to deliver anti-HIV biologics including bNAbs as a strategy to circumvent the need for continual antibody administration. Chimeric antigen receptor (CAR) T cell therapy is identified as a re-emerging HIV cure strategy, with improved CAR-T constructs now advancing to HIV-1 clinical trials. CRISPR-Cas9 gene editing has enabled complete excision of latent HIV-1 from the host genome in preclinical models, though success has thus far been limited.
More than half of investigational long-acting antivirals target HIV-1 RT and/or integrase. The INSTI class now includes four agents approved for treatment-naïve patients (raltegravir, elvitegravir, dolutegravir, bictegravir) and one long-acting formulation (cabotegravir). HIV-1 Capsid is an emerging target, with lenacapavir exemplifying clinical translation. The HIV-1 Envelope gp120/gp41 is the principal bNAb target, with conserved epitopes at the CD4bs, V2/V3 glycan shield, and MPER of gp41.
Still have questions? Let PatSnap Eureka search the HIV patent and literature database for you.
Ask PatSnap Eureka About the HIV PipelineAccelerate Your HIV Drug Discovery & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to map the HIV pipeline, identify white space, and monitor competitor filings across LAI-ART, bNAbs, and functional cure approaches.
References
- Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase — Karolinska Institute, 2019
- Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention — Chungnam National University School of Medicine, 2021
- A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV — University of Nebraska Medical Center, Scarsi et al., 2021
- Long-acting injectable antiretrovirals for HIV treatment and prevention — GlaxoSmithKline, 2013
- HIV Prevention Utilizing Long-acting Injectables — 2022
- Injectable Antiretroviral Drugs: Back to the Future — Vita-Salute San Raffaele University, 2021
- A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile — Fudan University, 2022
- Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action — Chinese Center for Disease Control and Prevention, 2019
- Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic — Oregon National Primate Research Center, Oregon Health & Science University, 2021
- Broadly Neutralizing Antibodies for HIV Eradication — Beth Israel Deaconess Medical Center, Harvard Medical School, 2016
- HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys — Gilead Sciences, 2022
- Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure — Amsterdam University Medical Center, 2021
- Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies — IrsiCaixa AIDS Research Institute, 2018
- Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies — Xiamen University, 2016
- Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics — Scripps Research Institute, 2020
- Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir — University of Pittsburgh School of Medicine, 2022
- Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV — Children's National Medical Center, 2020
- Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation — University of California, Davis, 2015
- The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate — Debiopharm International, 2019
- Anti-proliferative therapy for HIV cure: a compound interest approach — Fred Hutchinson Cancer Research Center, 2016
- Long-acting and extended-release implant and nanoformulations with a synergistic antiretroviral two-drug combination controls HIV-1 infection in a humanized mouse model — Yale University, 2021
- Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma — Department of Pharmaceutics, 2017
- Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages — University of Nebraska Medical Center, 2015
- UNAIDS — Global HIV & AIDS statistics — Joint United Nations Programme on HIV/AIDS
- NIAID — HIV/AIDS Research — National Institute of Allergy and Infectious Diseases
- ClinicalTrials.gov — HIV Long-Acting Injectable Trials — U.S. National Library of Medicine
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.